Global Rare Disease Treatment Market (Sales, Revenue, Price, Gross Profit and Competitors Analysis of Major Market) from 2015-2026
- Published Date: 2021-01-17
- Report ID: 38837
- Pages: 113
-
Format:
Summary
As the world continues to deal with COVID-19, economies are moving into recession, under multiple adverse factors, the GDP of European and American countries in the second quarter suffered a historical contraction. At an annualized rate, the US GDP fell by 32.9% month on month, while the overall GDP of the euro zone fell by 12.1%.
Moreover, the economic prospects of Europe and the United States in the third quarter under the epidemic situation are hardly optimistic. The resumption of work and production not only brought economic data back, but also triggered a rebound in the epidemic situation. At present, the United States is still the 'epicenter' of the global epidemic. The total number of confirmed cases has exceeded 4.8 million, and the epidemic situation in some European countries has also rebounded. Affected by this, more than 20 states in the United States have announced the suspension or withdrawal of part of the economic restart plan. Britain and Italy have also decided to extend the state of emergency. The rebound of the epidemic situation has posed considerable risks to the economic prospects of Europe and the United States.
In the second quarter of this year, US GDP shrank by 9.5% on a month on month basis, or 32.9% at an annual rate, the largest decline since the 1940s. Data show that the sharp decline in personal consumption is the main drag on the U.S. GDP growth in the second quarter.
Compared with the United States, Europe's economic contraction in the second quarter was smaller, but it was also the lowest on record, with Germany and France contracting more than 10%. According to the data released by the Federal Bureau of statistics, Germany's GDP fell by 10.1% in the second quarter after adjusting for prices, seasons and working days, the largest decline since the quarterly economic data were available in 1970.
Thanks to the effective control and policy support of the new epidemic, China's economy rebounded sharply in the second quarter. The growth rate of manufacturing industry, which accounted for about 28% of GDP, rebounded sharply to 4.4% from the negative value in the first quarter. Chinese original equipment manufacturers (OEMs) and suppliers are ramping up production. And there are increased investments in digital footprints in manufacturing. OEMs in other parts of the world are offering incentives to drive sales. Prudent Markets published a report for global Rare Disease Treatment market in this environment.
In terms of revenue, this research report indicated that the global Rare Disease Treatment market was valued at USD XXX million in 2019, and it is expected to reach a value of USD XXX million by 2026, at a CAGR of XX % over the forecast period 2021-2026. Correspondingly, the forecast analysis of Rare Disease Treatment industry comprises of China, USA, Japan, India, Korea and South America, with the production and revenue data in each of the sub-segments.
The Novartis aims at producing XX Rare Disease Treatment in 2020, with XX % production to take place in global market, Pfizer accounts for a volume share of XX %.
Regional Segmentation (Value; Revenue, USD Million, 2015 - 2026) of Rare Disease Treatment Market by Prudent Markets Include
China
EU
USA
Japan
India
Southeast Asia
South America
Competitive Analysis; Who are the Major Players in Rare Disease Treatment Market
Novartis
Pfizer
F. Hoffmann-La Roche
Celgene
AbbVie
Johnson and Johnson
Shire
Alexion
Novo Nordisk
Sanofi
Bayer
Amgen
Allergan
Eisai
Bristol-Myers Squibb
Merck
Vertex Pharmaceuticals
Baxter
BioMarin
Teva Pharmaceutical Industries
...
Major Type of Rare Disease Treatment Covered in Prudent Markets report:
Originator Drugs
Generic Drugs
Application Segments Covered in Prudent Markets Market
Hospital Pharmacies
Specialty Pharmacies
Retail Pharmacies
For any other requirements, please feel free to contact us and we will provide you customized report.
Table of Contents
Global Rare Disease Treatment Market Analysis 2020, With Top Companies, Production, Revenue, Consumption, Price and Growth Rate
1 Market Scope
1.1 Product Details and Introduction
1.1.1 Originator Drugs -Product Introduction and Major Manufacturers
1.1.2 Generic Drugs -Product Introduction and Major Manufacturers
1.2 Market Snapshot
1.2.1 Major Companies Overview
1.2.2 Market Concentration
1.2.3 Six-Year Compound Annual Growth Rate (CAGR)
2 Global Rare Disease Treatment Market Assessment, by Segmentation
2.1 Type Breakdown Estimates & Forecast, Sales Volume (2015-2026)
2.2 Type Breakdown Estimates & Forecast, Sales Value (2015-2026)
2.3 Application Breakdown Estimates & Forecast, by Application (2015-2026)
3 Regional Market Analysis
3.1 China Rare Disease Treatment Market
3.1.1 Top Companies leading Rare Disease Treatment Development in China (2015-2020)
3.1.2 Sales Value of Major Company in China Market (2015-2020)
3.1.3 China Rare Disease Treatment Price (USD/Unit), by Type (2019-2020)
3.1.4 Sales in China Market, by Type (2015-2026)
3.2 EU Rare Disease Treatment Market
3.2.1 Top Companies leading Rare Disease Treatment Development in EU (2015-2020)
3.2.2 Sales Value of Major Company in EU Market (2015-2020)
3.2.3 EU Rare Disease Treatment Price (USD/Unit), by Type (2019-2020)
3.2.4 Sales in EU Market, by Type (2015-2026)
3.3 USA Rare Disease Treatment Market
3.3.1 Top Companies leading Rare Disease Treatment Development in USA (2015-2020)
3.3.2 Sales Value of Major Company in USA Market (2015-2020)
3.3.3 USA Rare Disease Treatment Price (USD/Unit), by Type (2019-2020)
3.3.4 Sales in USA Market, by Type (2015-2026)
3.4 Japan Rare Disease Treatment Market
3.4.1 Top Companies leading Rare Disease Treatment Development in Japan (2015-2020)
3.4.2 Sales Value of Major Company in Japan Market (2015-2020)
3.4.3 Japan Rare Disease Treatment Price (USD/Unit), by Type (2019-2020)
3.4.4 Sales in Japan Market, by Type (2015-2026)
3.5 India Rare Disease Treatment Market
3.5.1 Top Companies leading Rare Disease Treatment Development in India (2015-2020)
3.5.2 Sales Value of Major Company in India Market (2015-2020)
3.5.3 India Rare Disease Treatment Price (USD/Unit), by Type (2019-2020)
3.5.4 Sales in India Market, by Type (2015-2026)
3.6 Southeast Asia Rare Disease Treatment Market
3.6.1 Top Companies leading Rare Disease Treatment Development in Southeast Asia (2015-2020)
3.6.2 Sales Value of Major Company in Southeast Asia Market (2015-2020)
3.6.3 Southeast Asia Rare Disease Treatment Price (USD/Unit), by Type (2019-2020)
3.6.4 Sales in Southeast Asia Market, by Type (2015-2026)
3.7 South America Rare Disease Treatment Market
3.7.1 Top Companies leading Rare Disease Treatment Development in South America (2015-2020)
3.7.2 Sales Value of Major Company in South America Market (2015-2020)
3.7.3 South America Rare Disease Treatment Price (USD/Unit), by Type (2019-2020)
3.7.4 Sales in South America Market, by Type (2015-2026)
4 Value Chain (Impact of COVID-19)
4.1 Rare Disease Treatment Value Chain Analysis
4.1.1 Upstream
4.1.2 Downstream
4.2 COVID-19 Impact on Rare Disease Treatment Industry
4.2.1 Industrial Policy Issued Under the Epidemic Situation
4.3 Cost-Under the Epidemic Situation
4.3.1 Cost of Raw Material
4.4 Channel Analysis
4.4.1 Distribution Channel-Under the Epidemic Situation
4.4.2 Distributors
5 Regional Market Forecast (2021-2026)
5.1 Global Rare Disease Treatment Sales and Growth Rate (2021-2026)
5.2 Global Rare Disease Treatment Sales Value and Growth Rate (2021-2026)
6 Rare Disease Treatment Competitive Analysis
6.1 Novartis
6.1.1 Novartis Company Profiles
6.1.2 Novartis Product Introduction
6.1.3 Novartis Rare Disease Treatment Production, Revenue (2015-2020)
6.1.4 SWOT Analysis
6.2 Pfizer
6.2.1 Pfizer Company Profiles
6.2.2 Pfizer Product Introduction
6.2.3 Pfizer Rare Disease Treatment Production, Revenue (2015-2020)
6.2.4 SWOT Analysis
6.3 F. Hoffmann-La Roche
6.3.1 F. Hoffmann-La Roche Company Profiles
6.3.2 F. Hoffmann-La Roche Product Introduction
6.3.3 F. Hoffmann-La Roche Rare Disease Treatment Production, Revenue (2015-2020)
6.3.4 SWOT Analysis
6.4 Celgene
6.4.1 Celgene Company Profiles
6.4.2 Celgene Product Introduction
6.4.3 Celgene Rare Disease Treatment Production, Revenue (2015-2020)
6.4.4 SWOT Analysis
6.5 AbbVie
6.5.1 AbbVie Company Profiles
6.5.2 AbbVie Product Introduction
6.5.3 AbbVie Rare Disease Treatment Production, Revenue (2015-2020)
6.5.4 SWOT Analysis
6.6 Johnson and Johnson
6.6.1 Johnson and Johnson Company Profiles
6.6.2 Johnson and Johnson Product Introduction
6.6.3 Johnson and Johnson Rare Disease Treatment Production, Revenue (2015-2020)
6.6.4 SWOT Analysis
6.7 Shire
6.7.1 Shire Company Profiles
6.7.2 Shire Product Introduction
6.7.3 Shire Rare Disease Treatment Production, Revenue (2015-2020)
6.7.4 SWOT Analysis
6.8 Alexion
6.8.1 Alexion Company Profiles
6.8.2 Alexion Product Introduction
6.8.3 Alexion Rare Disease Treatment Production, Revenue (2015-2020)
6.8.4 SWOT Analysis
6.9 Novo Nordisk
6.9.1 Novo Nordisk Company Profiles
6.9.2 Novo Nordisk Product Introduction
6.9.3 Novo Nordisk Rare Disease Treatment Production, Revenue (2015-2020)
6.9.4 SWOT Analysis
6.10 Sanofi
6.10.1 Sanofi Company Profiles
6.10.2 Sanofi Product Introduction
6.10.3 Sanofi Rare Disease Treatment Production, Revenue (2015-2020)
6.10.4 SWOT Analysis
6.11 Bayer
6.12 Amgen
6.13 Allergan
6.14 Eisai
6.15 Bristol-Myers Squibb
6.16 Merck
6.17 Vertex Pharmaceuticals
6.18 Baxter
6.19 BioMarin
6.20 Teva Pharmaceutical Industries
7 Conclusion
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
